AstraZeneca: Liver Cirrhosis trials
The registry lists 11 Liver Cirrhosis studies with AstraZeneca as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 5Phase 2 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisRecruitingNCT07610837Phase 2
- A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.CompletedNCT06750276Phase 2Results posted
- A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCKCompletedNCT06269484Phase 2Results posted
- A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedNCT05809934Phase 2Results posted
- Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)TerminatedNCT05516498Phase 2Results posted
- A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedNCT05364931Phase 2Results posted
- The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.CompletedNCT07069725Phase 1
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With QuinidineCompletedNCT06974565Phase 1
- A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy ParticipantsCompletedNCT06973005Phase 1
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389CompletedNCT06812780Phase 1
- A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese ParticipantsCompletedNCT06715670Phase 1